Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF3 | O95398 | 12/20 | 0.56 |
| ▸ | RAPGEF4 | Q8WZA2 | 7/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14153611 | 0.72 | SLC1A2 (0.47) | ALDH1A1 | |
| SCHEMBL18899276 | 0.71 | ALDH1A1 (0.48) | RAPGEF3RAPGEF4GAACYP3A4ALOX5 | |
| Hydrazobenzene SCHEMBL10946311 | 0.70 | ALDH1A1 (0.67) | GAACYP3A4ALOX5TSHRPTGS2 | |
| SCHEMBL13546618 | 0.67 | ALDH1A1 (0.47) | GAACYP3A4TSHRMAPTGFER | |
| Phenicarbazide SCHEMBL250264 | 0.65 | ALOX5 (0.61) | GAACYP3A4ALOX5TSHRPTGS2 | |
| SCHEMBL22856571 | 0.65 | ALOX5 (0.61) | GAACYP3A4ALOX5TSHRPTGS2 | |
| SCHEMBL2927032 | 0.64 | TSHR (0.48) | ALOX5TSHRCYP2C19ALDH1A1CTSD | |
| SCHEMBL2771881 | 0.64 | TSHR (0.48) | ALOX5TSHRCYP2C19ALDH1A1CTSD | |
| SCHEMBL1339975 | 0.64 | GAA (0.55) | GAACYP3A4ALOX5TSHRPTGS2 | |
| SCHEMBL27848926 | 0.64 | ALOX5 (0.55) | GAACYP3A4ALOX5TSHRPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264439-A1 | Inhibitors of polo-like kinase-1 | SUPERGEN, INC. (US) | 2006-11-23 | — | — | US | disclosed |
| WO-2006124996-A2 | INHIBITORS OF POLO-LIKE KINASE-1 | SUPERGEN, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264439-A1 | Inhibitors of polo-like kinase-1 | PLK2, PHKG1, PRKDC | RAPGEF3 1182/4885RAPGEF4 1622/4885GAA 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.